Pancreatic Cancer Research

ResearcherTohoku UniversityActive in the last 2 years

Kei Nakagawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3058-5674; OpenAlex author ID A5011710526. Sources: OpenAlex.

Their work

Papers
42 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
78
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 4 papers · 2018: 1 paper · 2019: 1 paper · 2020: 4 papers · 2021: 8 papers · 2022: 5 papers · 2023: 8 papers · 2024: 3 papers · 2025: 4 papers

Papers 42

  1. Fecal colitis obliterans and cytomegalovirus enteritis after pancreaticoduodenectomy for resectable pancreatic cancer. Co-author DOI 10.1007/s12328-025-02219-7↗
  2. Outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1 treatment: A propensity sco… Co-author DOI 10.1016/j.pan.2025.08.017↗
  3. Transcriptional regulation of ETV5 by mitogen-activated protein kinase via ETS-1 in human pancreatic cancer cells. Co-author DOI 10.1038/s41598-025-97166-1↗
  4. Preoperative Chemotherapy With Gemcitabine for Pancreatic Cancer Causes Zinc Deficiency. Co-author DOI 10.1097/mpa.0000000000002396↗
  5. GFPT2 expression is induced by gemcitabine administration and enhances invasion by activating the hexosamine biosynthetic pathway in pancreatic cancer. Co-author DOI 10.1007/s10585-024-10298-y↗
  6. Deep learning predicts the 1-year prognosis of pancreatic cancer patients using positive peritoneal washing cytology. Co-author DOI 10.1038/s41598-024-67757-5↗
  7. Machine Learning of Histopathological Images Predicts Recurrences of Resected Pancreatic Ductal Adenocarcinoma With Adjuvant Treatment. Co-author DOI 10.1097/mpa.0000000000002289↗
  8. Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical … Co-author DOI 10.1002/jhbp.1282↗
  9. Expression of Corticotropin-Releasing Hormone and Its Receptors May Be Associated With Survival Rate in Pancreatic Cancer. Co-author DOI 10.1016/j.gastha.2022.09.003↗
  10. GATA6 and CK5 Stratify the Survival of Patients With Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy. Co-author DOI 10.1016/j.modpat.2023.100102↗
  11. Negative prognostic impact of sarcopenia before and after neoadjuvant chemotherapy for pancreatic cancer. Co-author DOI 10.1016/j.pan.2022.11.010↗
  12. Clinical impact of multimodal treatment including chemoradiotherapy, conversion surgery and postoperative chemotherapy for borderline resectable and unresectab… Co-author DOI 10.1016/j.pan.2023.07.002↗
  13. Reduced expression of phosphorylated ataxia-telangiectasia mutated gene is related to poor prognosis and gemcitabine chemoresistance in pancreatic cancer. Co-author DOI 10.1186/s12885-023-11294-3↗
  14. CA19-9 With Two-stage Resection Is Useful for Conversion Surgery in PDAC With Synchronous Oligometastases. Co-author DOI 10.21873/anticanres.16724↗
  15. [A Case of an Elderly Patient Who Underwent Conversion Resection for Pancreatic Cancer with Positive Peritoneal Cytology]. Co-author PMID 36807179↗
  16. Levels of tumor markers CEA/CA 19-9 in serum and peritoneal lavage predict postoperative recurrence in patients with pancreatic cancer. Co-author DOI 10.1002/ags3.12597↗
  17. What is the impact of zinc deficiency for pancreatectomies in patients with pancreatic ductal adenocarcinoma? Co-author DOI 10.1016/j.pan.2021.12.006↗
  18. Clinical features and prognostic impact of asymptomatic pancreatic cancer. Co-author DOI 10.1038/s41598-022-08083-6↗
  19. Comparison of acute gastrointestinal toxicities between 3-dimensional conformal radiotherapy and intensity-modulated radiotherapy including prophylactic region… First author DOI 10.1093/jrr/rrac049↗
  20. Impact of Tumor-Derived DNA Testing in Peritoneal Lavage of Pancreatic Cancer Patients with and Without Occult Intra-Abdominal Metastases. Co-author DOI 10.1245/s10434-021-10997-w↗
  21. Germline DNA damage repair gene mutations in pancreatic cancer patients with personal/family histories of pancreas/breast/ovarian/prostate cancer in a Japanese… Co-author DOI 10.1002/ags3.12482↗
  22. Circulating tumor DNA as a predictive marker for occult metastases in pancreatic cancer patients with radiographically non-metastatic disease. Co-author DOI 10.1002/jhbp.993↗
  23. Staging laparoscopy is mandatory for the treatment of pancreatic cancer to avoid missing radiologically negative metastases. Co-author DOI 10.1007/s00595-020-02121-4↗
  24. Prognostic value of an inflammation-based nutritional score for patients with initially unresectable pancreatic adenocarcinoma undergoing conversion surgery fo… Co-author DOI 10.1007/s00595-021-02279-5↗
  25. Silencing of LRRFIP1 enhances the sensitivity of gemcitabine in pancreatic cancer cells by activating JNK/c-Jun signaling. Co-author DOI 10.1016/j.pan.2021.02.018↗
  26. MicroRNA-593-3p Expression in Peritoneal Lavage Fluid as a Prognostic Marker for Pancreatic Cancer Patients Undergoing Staging Laparoscopy. Co-author DOI 10.1245/s10434-020-09440-3↗
  27. Preceding Systemic Chemotherapy for Patients with Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology Provides Survival Benefit Compared with Up… Co-author DOI 10.1245/s10434-021-09718-0↗
  28. Stomatin‑like protein 2 induces metastasis by regulating the expression of a rate‑limiting enzyme of the hexosamine biosynthetic pathway in pancreatic cancer. Co-author DOI 10.3892/or.2021.8041↗
  29. Prognostic indicators in pancreatic cancer patients undergoing total pancreatectomy. Co-author DOI 10.1007/s00595-019-01924-4↗
  30. Prognostic impact of intraoperative peritoneal cytology after neoadjuvant therapy for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.08.022↗
  31. Stromal expression of hemopexin is associated with lymph-node metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0235904↗
  32. [A Case of Initially Locally Advanced Pancreatic Cancer Curatively Resected after Carbon-Ion Radiotherapy with Gemcitabine]. Co-author PMID 33468929↗
  33. Collagen gel droplet-embedded culture drug sensitivity test (CD-DST) predicts the effect of adjuvant chemotherapy on pancreatic cancer. Co-author DOI 10.1007/s00595-019-01842-5↗
  34. Association between chronological depressive changes and physical symptoms in postoperative pancreatic cancer patients. Co-author DOI 10.1186/s13030-018-0132-1↗
  35. Predictive risk factors for peritoneal recurrence after pancreatic cancer resection and strategies for its prevention. Co-author DOI 10.1007/s00595-017-1531-9↗
  36. Locally advanced pancreatic cancer successfully treated by distal pancreatectomy with celiac axis resection (DP-CAR) after S-1 with radiation therapy followed … Co-author DOI 10.1186/s40792-017-0290-6↗
  37. A long-term survival case treated with conversion surgery following chemotherapy after diagnostic metastasectomy for pancreatic cancer with synchronous liver m… Co-author DOI 10.1186/s40792-017-0409-9↗
  38. [Multidisciplinary Therapy with Gemcitabine and Nab-Paclitaxel for Unresectable Pancreatic Cancer]. Co-author PMID 29394594↗
  39. [A Case of Successful Stomach-Preserving Pancreaticoduodenectomy with Celiac Artery Resection after Neoadjuvant Chemoradiation Therapy for Pancreatic Cancer wi… Co-author PMID 28133191↗
  40. [A case of pancreatic cancer with local recurrence and liver metastases eight years after surgery]. Co-author PMID 25731467↗
  41. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutiona… Co-author DOI 10.1245/s10434-013-3129-9↗
  42. [A case of successful R0 resection after neoadjuvant therapy for locally advanced unresectable pancreatic cancer]. Co-author PMID 24393949↗

Closest collaborators

The 25 strongest of 78 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michiaki Unno · 40 shared papers, 2013–2025 · strength 4.87
  2. Masamichi Mizuma · 36 shared papers, 2013–2025 · strength 4.47
  3. Takanori Morikawa · 27 shared papers, 2013–2023 · strength 2.94
  4. Fuyuhiko Motoi · 26 shared papers, 2013–2023 · strength 2.60
  5. Kyohei Ariake · 15 shared papers, 2017–2024 · strength 1.54
  6. Shuichi Aoki · 11 shared papers, 2013–2025 · strength 1.42
  7. Shimpei Maeda · 13 shared papers, 2017–2025 · strength 1.39
  8. Tatsuo Hata · 11 shared papers, 2017–2023 · strength 1.31
  9. Daisuke Douchi · 8 shared papers, 2021–2025 · strength 1.29
  10. Masahiro Iseki · 10 shared papers, 2017–2025 · strength 1.28
  11. Tatsuyuki Takadate · 13 shared papers, 2016–2023 · strength 1.22
  12. Takashi Kokumai · 7 shared papers, 2021–2025 · strength 1.21
  13. Toru Furukawa · 7 shared papers, 2021–2025 · strength 1.16
  14. Kei Kawaguchi · 8 shared papers, 2014–2023 · strength 0.84
  15. Yu Katayose · 6 shared papers, 2013–2025 · strength 0.58
  16. Aya Noguchi · 3 shared papers, 2024–2025 · strength 0.57
  17. Mitsuhiro Shimura · 4 shared papers, 2017–2025 · strength 0.50
  18. Kazuharu Chiba · 3 shared papers, 2021–2022 · strength 0.42
  19. Yuko Omori · 2 shared papers, 2023–2025 · strength 0.38
  20. Koetsu Inoue · 2 shared papers, 2023–2025 · strength 0.36
  21. Jingyu Xun · 2 shared papers, 2023–2024 · strength 0.36
  22. Ruri Yamaguchi · 2 shared papers, 2024 · strength 0.34
  23. Keiichi Jingu · 2 shared papers, 2022–2023 · strength 0.32
  24. Rei Umezawa · 2 shared papers, 2022–2023 · strength 0.32
  25. Koetsu Inoue · 2 shared papers, 2023 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.